Late-stage HIV drug trial delivers positive data

Canada's Theratechnologies says that a Phase III trial of its experimental HIV therapy hit its primary endpoint. TH9507, a therapy for HIV's side effects, demonstrated an average 15 percent reduction in visceral adipose tissue versus baseline and 20 percent reduction versus a placebo following 26 weeks of therapy. The trial goal was an eight percent reduction in visceral adipose tissue. Researchers say they hope to replicate those results in a new study scheduled to get underway in early 2007.

"The emerging efficacy/safety profile of TH9507 is exactly what we were hoping for," says CEO Yves Rosconi. "It has great prospects as a treatment for excess visceral fat accumulation in HIV patients, with potential advantages over other approaches being developed."

- here's the release on the trial data

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.